List: 25 highest-paid women in biotech; GSK seals $3.6B HGS deal;

Conversations on Twitter :

 @FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech

 @JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce

 @RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce

> GEN rounded up the top 25 most highly paid women in biotech, and three of them appear to have CEO in their titles. Heather Bresch, CEO of Mylan ($MYL), topped the list with 2011 compensation of $9.6 million. Item

> Elusys has grabbed a $50.2 million award from Uncle Sam to develop its anthrax treatment. Article

> Furiex Pharmaceuticals ($FURX) has added $30 million to a $10 million loan, striking a debt agreement with Silicon Valley Bank and MidCap Financial. Release

> Xconomy covered San Diego-based drug developers Sophiris Bio's journey to break into the blockbuster market for prostate cancer drugs. Article

> As expected, GlaxoSmithKline ($GSK) has wrapped up its $3.6 billion buyout of U.S. biotech and long-time partner Human Genome Sciences. Item

Pharma News

 @FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street Journal. More | Follow @FiercePharma

> J&J acknowledges what everyone knows, it settled with DoJ. Story

> Johnson & Johnson releases some Doxil for trials. More

> Investors bite on Pfizer's Sandwich site. News

> GSK tries volume, goodwill, over margins in Africa. Article

> Bloomberg: India's Sun sizes up deal with Germany's Stada. Story

Medical Device News

@FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev

 @MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce

 @DamianFierce: NEJM: FDA device approval no slower than EU's. More | Follow @DamianFierce

> NEJM: FDA device approval no slower than EU's. Report

> CA hospital accused of testing Stryker tech without patient consent. Article

> FDA whacks Philips unit with Class I ventilator recall. News

And Finally… Taxes hurt U.S. cigarette sales as smokers take alternative smoking measures. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.